Moleculin Biotech, Inc. (MBRX)
7.90
-0.82
(-9.40%)
USD |
NASDAQ |
Oct 30, 16:00
8.10
+0.20
(+2.53%)
After-Hours: 20:00
Moleculin Biotech Net Income (Quarterly) : -7.635M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -7.635M |
| March 31, 2026 | -12.84M |
| December 31, 2025 | 15.55M |
| September 30, 2025 | -25.40M |
| June 30, 2025 | -17.81M |
| March 31, 2025 | -5.904M |
| December 31, 2024 | -6.584M |
| September 30, 2024 | -7.024M |
| June 30, 2024 | -4.319M |
| March 31, 2024 | -4.97M |
| December 31, 2023 | -10.27M |
| September 30, 2023 | -5.609M |
| June 30, 2023 | -5.976M |
| March 31, 2023 | -7.915M |
| December 31, 2022 | -6.77M |
| September 30, 2022 | -8.611M |
| June 30, 2022 | -6.777M |
| March 31, 2022 | -6.867M |
| December 31, 2021 | -2.825M |
| September 30, 2021 | -4.379M |
| June 30, 2021 | -4.244M |
| March 31, 2021 | -4.445M |
| Date | Value |
|---|---|
| December 31, 2020 | -2.639M |
| September 30, 2020 | -3.395M |
| June 30, 2020 | -10.11M |
| March 31, 2020 | -1.209M |
| December 31, 2019 | -3.797M |
| September 30, 2019 | -4.145M |
| June 30, 2019 | -1.221M |
| March 31, 2019 | -4.041M |
| December 31, 2018 | -2.785M |
| September 30, 2018 | -2.038M |
| June 30, 2018 | -5.125M |
| March 31, 2018 | -1.927M |
| December 31, 2017 | -3.185M |
| September 30, 2017 | -2.866M |
| June 30, 2017 | -3.424M |
| March 31, 2017 | -0.329M |
| December 31, 2016 | -1.423M |
| September 30, 2016 | -1.432M |
| June 30, 2016 | -0.7387M |
| March 31, 2016 | -0.3322M |
| December 31, 2015 | -0.524M |
| September 30, 2015 | -0.2243M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 7.635M |
| EPS Diluted (Quarterly) | -28.04 |
| Enterprise Value | -4.166M |
| Earnings Yield | -4.34K% |
| Normalized Earnings Yield | -3760.45 |